Strategies for successful clinical management of schizophrenia with ziprasidone.
作者： Andrea Fagiolini , Fernando Cañas , Bernd Gallhofer , Ilkka Larmo , Pedro Levy
DOI: 10.1517/14656566.2010.507630
关键词:
摘要: Importance of the field: This review addresses practical clinical issues related to use ziprasidone in treatment schizophrenia using information from trials, unpublished data, manufacturer's information, and input an expert faculty European psychiatrists with extensive experience ziprasidone, both trials everyday practice.Areas covered this review: A Medline search published data (1998 – 2010) was carried out, together a information. In addition, opinion sought settings across Europe.What reader will gain: has been undertaken determine how can be optimally translated into ‘real-life’ practice establish decade inform its optimal maxim...
core.ac.uk
informahealthcare.com参考文章(68)
Donald E Addington, Alain Labelle, Jayashri Kulkarni, Gordon Johnson, Antony Loebel, Francine S Mandel, A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study The Canadian Journal of Psychiatry. ,vol. 54, pp. 46- 54 ,(2009) , 10.1177/070674370905400108
Stephen M. Stahl, Cristina Damatarca, Lishu Zhang, Meghan Grady, Brain Circuits Determine Destiny in Depression: A Novel Approach to the Psychopharmacology of Wakefulness, Fatigue, and Executive Dysfunction in Major Depressive Disorder. The Journal of Clinical Psychiatry. ,vol. 64, pp. 6- 17 ,(2003)
Prakash S. Masand, Charles B. Nemeroff, John W. Newcomer, Jeffrey A. Lieberman, Alan F. Schatzberg, Peter J. Weiden, Clinton D. Kilts, Philip D. Harvey, David G. Daniel, From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone CNS Spectrums. ,vol. 10, pp. 1- 20 ,(2005) , 10.1017/S1092852900019842
Philip D. Harvey, Ziprasidone and cognition: the evolving story. The Journal of Clinical Psychiatry. ,vol. 64, pp. 33- 39 ,(2003)
C Arango, M Gómez-Beneyto, J Brenlla, C Gastó, F Sarramea-Crespo, L Chamorro, X Masramon, T Díez, ZIS Study Group, A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. European Neuropsychopharmacology. ,vol. 17, pp. 456- 463 ,(2007) , 10.1016/J.EURONEURO.2006.11.007
Marc Ziegenbein, Iris T. Calliess, Clozapine and Ziprasidone: A Useful Combination in Patients With Treatment-Resistant Schizophrenia Journal of Neuropsychiatry and Clinical Neurosciences. ,vol. 18, pp. 246- 247 ,(2006) , 10.1176/JNP.2006.18.2.246
Steven G. Potkin, Paul E. Keck, Scott Segal, Kathleen Ice, Patricia English, Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. Journal of Clinical Psychopharmacology. ,vol. 25, pp. 301- 310 ,(2005) , 10.1097/01.JCP.0000169068.34322.70
Anne W Schmidt, Lorraine A Lebel, Harry R Howard, Stevin H Zorn, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile European Journal of Pharmacology. ,vol. 425, pp. 197- 201 ,(2001) , 10.1016/S0014-2999(01)01188-8
Koksal Alptekin, Jamal Hafez, Shlomo Brook, Cengiz Akkaya, Errikos Tzebelikos, Alp Ucok, Hamdy El Tallawy, Aysen-Esen Danaci, Wing Lowe, Onur N. Karayal, Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. International Clinical Psychopharmacology. ,vol. 24, pp. 229- 238 ,(2009) , 10.1097/YIC.0B013E32832C2624
M Zink, A Kuwilsky, B Krumm, H Dressing, Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology. ,vol. 23, pp. 305- 314 ,(2009) , 10.1177/0269881108089593